Vardenafil Oral Dispersible Films (ODFs) with Advanced Dissolution, Palatability, and Bioavailability

Dosing frequency should not exceed one dose per 24-hour period to minimize cumulative exposure and adverse events. Patients receiving potent CYP3A4 inhibitors may require maximum doses of 2.5-5 mg no more than once in 72 hours. The erectile response is a neurovascular event initiated by parasympathetic-mediated nitric oxide (NO) release from cavernous nerve terminals and endothelial cells. NO stimulates guanylate cyclase, increasing intracellular cGMP, which in turn lowers intracellular calcium and relaxes trabecular smooth muscle. PDE5 terminates this signal by hydrolyzing cGMP to its inactive 5′ monophosphate. Vardenafil binds selectively and reversibly to the catalytic site of PDE5, raising cGMP concentrations and amplifying the natural erectile cascade in the presence of sexual arousal. In vitro affinity profiling demonstrates that vardenafil exhibits a 10- to 20-fold greater potency against PDE5 than sildenafil and maintains over 1000-fold selectivity versus other cyclic nucleotide phosphodiesterases, including the cardiac isoenzyme PDE3 and retinal PDE6.

Factors Influencing Vardenafil Onset: Key Considerations

Similarly, patients receiving riociguat, a soluble guanylate-cyclase stimulator, should avoid vardenafil because the combination can produce profound systemic blood-pressure reductions unresponsive to vasopressors. Prescribers must inquire specifically about intermittent nitrate use for angina prior to initiating therapy. Individuals with inherited degenerative retinal disorders such as retinitis pigmentosa, although representing less than one percent of the population, were excluded from pivotal trials; theoretical PDE6 cross-reactivity raises concerns about exacerbating photoreceptor degeneration. Vardenafil should also be withheld in patients with known hypersensitivity to the drug or its excipients. Electrocardiographic studies revealed small, dose-dependent increases in QTc (approximately 4-6 ms) at supratherapeutic exposures; consequently, vardenafil is contraindicated in men taking class IA or class III anti-arrhythmic agents (e.g., quinidine, procainamide, amiodarone, sotalol) or in those with congenital long-QT syndrome.

Mechanism of Action

Additional caution is warranted following recent (< 6 months) myocardial infarction, stroke, or life-threatening arrhythmia, and in patients with uncontrolled hypertension (≥ 170/100 mm Hg), severe hypotension (< 90/50 mm Hg), or severe hepatic impairment (Child-Pugh C). Data from pooled cardiovascular safety analyses indicate that men with stable coronary artery disease who are not taking nitrates do not experience an increased incidence of major adverse cardiac events when treated with PDE5 inhibitors; however, clinical judgment should prevail for each patient’s fildena 200 mg risk-benefit assessment. Pharmacokinetic interactions largely stem from vardenafil’s metabolism by CYP3A4. For example, concomitant ketoconazole 400 mg once daily increased vardenafil area under the curve (AUC) nearly ten-fold; under such circumstances, dosing should not exceed 2.5 mg in 24 hours. Combined use with α-adrenergic blockers (e.g., doxazosin, terazosin) may potentiate orthostatic hypotension due to overlapping vasodilatory effects.

Are you currently using Vardenafil (Levitra, Staxyn)?

Titrate the α-blocker to a stable maintenance dose and ensure hemodynamic stability before introducing vardenafil at the lowest feasible dose. Clinical pharmacology trials evaluating co-administration with tamsulosin 0.4 mg daily demonstrated no clinically significant blood-pressure reductions when vardenafil was given two hours after the α-blocker, underscoring the importance of temporal separation and dose adjustment. Additional interactions include moderate CYP3A4 inducers (e.g., rifampin, carbamazepine), which can lower systemic exposure, potentially requiring dosage escalation if clinically justified. Grapefruit juice inhibits enteric CYP3A4 and may unpredictably increase vardenafil bioavailability; patients should be advised to avoid large quantities or to maintain consistent intake patterns to minimize variability. Pharmacodynamic synergy with other vasodilators, antihypertensives, or alcohol could accentuate blood-pressure reductions, warranting patient counseling on positional dizziness and syncope risk. This selectivity profile reduces the likelihood of off-target hemodynamic or visual disturbances, although minor, transient alterations in color discrimination have been documented.

These interactions stabilize the inhibitor-enzyme complex, yielding an inhibitory constant (K_i) in the low nanomolar range. Following oral ingestion of a 20 mg tablet, mean vardenafil C_max approximates 20 ng mL⁻¹, with systemic exposure proportional across a 5-20 mg dose span. Metabolic clearance is dominated by oxidative N-dealkylation and ring hydroxylation, producing an active metabolite (M1) that retains ~28 % of parent potency but constitutes less than 7 % of the circulating molar fraction. Because PDE5 predominates in erectile tissue, systemic vasodilatory effects are typically modest at therapeutic doses. Nonetheless, vardenafil can synergize with exogenous NO donors, precipitating pronounced hypotension if nitrates or soluble guanylate-cyclase stimulators are co-administered.

What should I know about storage and disposal of this medication?

Optimization of factors affecting vardenafil absorption using β-cyclodextrin. Pharmaceutical Development and Technology, 24(3), 354-364. Korean Journal of Urology, 47(9), 1001-1008. Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs, 4(5), 281-297. Absolute contraindications include concurrent use of organic nitrates (e.g., nitroglycerin, isosorbide dinitrate) in any form. Co-administration may lead to severe, potentially life-threatening hypotension owing to additive increases in cGMP-mediated vasodilation.

Get Levitra Generic (Vardenafil) 20mg Online Prescription

Dosing frequency should not exceed one dose per 24-hour period to minimize cumulative exposure and adverse events. Patients receiving potent CYP3A4 inhibitors may require maximum doses of 2.5-5 mg no more than once in 72 hours. The erectile response is a neurovascular event initiated by parasympathetic-mediated nitric oxide (NO) release from cavernous nerve terminals and endothelial cells. NO stimulates guanylate cyclase, increasing intracellular cGMP, which in turn lowers intracellular calcium and relaxes trabecular smooth muscle. PDE5 terminates this signal by hydrolyzing cGMP to its inactive 5′ monophosphate.

Corresponding author

Vardenafil binds selectively and reversibly to the catalytic site of PDE5, raising cGMP concentrations and amplifying the natural erectile cascade in the presence of sexual arousal. In vitro affinity profiling demonstrates that vardenafil exhibits a 10- to 20-fold greater potency against PDE5 than sildenafil and maintains over 1000-fold selectivity versus other cyclic nucleotide phosphodiesterases, including the cardiac isoenzyme PDE3 and retinal PDE6. This selectivity profile reduces the likelihood of off-target hemodynamic or visual disturbances, although minor, transient alterations in color discrimination have been documented. These interactions stabilize the inhibitor-enzyme complex, yielding an inhibitory constant (K_i) in the low nanomolar range. Following oral ingestion of a 20 mg tablet, mean vardenafil C_max approximates 20 ng mL⁻¹, with systemic exposure proportional across a 5-20 mg dose span.

More common

Metabolic clearance is dominated by oxidative N-dealkylation and ring hydroxylation, producing an active metabolite (M1) that retains ~28 % of parent potency but constitutes less than 7 % of the circulating molar fraction. Because PDE5 predominates in erectile tissue, systemic vasodilatory effects are typically modest at therapeutic doses. Nonetheless, vardenafil can synergize with exogenous NO donors, precipitating pronounced hypotension if nitrates or soluble guanylate-cyclase stimulators are co-administered. Absolute contraindications include concurrent use of organic nitrates (e.g., nitroglycerin, isosorbide dinitrate) in any form. Co-administration may lead to severe, potentially life-threatening hypotension owing to additive increases in cGMP-mediated vasodilation. Similarly, patients receiving riociguat, a soluble guanylate-cyclase stimulator, should avoid vardenafil because the combination can produce profound systemic blood-pressure reductions unresponsive to vasopressors. Prescribers must inquire specifically about intermittent nitrate use for angina prior to initiating therapy. Individuals with inherited degenerative retinal disorders such as retinitis pigmentosa, although representing less than one percent of the population, were excluded from pivotal trials; theoretical PDE6 cross-reactivity raises concerns about exacerbating photoreceptor degeneration. Vardenafil should also be withheld in patients with known hypersensitivity to the drug or its excipients. Electrocardiographic studies revealed small, dose-dependent increases in QTc (approximately 4-6 ms) at supratherapeutic exposures; consequently, vardenafil is contraindicated in men taking class IA or class III anti-arrhythmic agents (e.g., quinidine, procainamide, amiodarone, sotalol) or in those with congenital long-QT syndrome. Additional caution is warranted following recent (< 6 months) myocardial infarction, stroke, or life-threatening arrhythmia, and in patients with uncontrolled hypertension (≥ 170/100 mm Hg), severe hypotension (< 90/50 mm Hg), or severe hepatic impairment (Child-Pugh C).

Data from pooled cardiovascular safety analyses indicate that men with stable coronary artery disease who are not taking nitrates do not experience an increased incidence of major adverse cardiac events when treated with PDE5 inhibitors; however, clinical judgment should prevail for each patient’s fildena 200 mg risk-benefit assessment. Pharmacokinetic interactions largely stem from vardenafil’s metabolism by CYP3A4. For example, concomitant ketoconazole 400 mg once daily increased vardenafil area under the curve (AUC) nearly ten-fold; under such circumstances, dosing should not exceed 2.5 mg in 24 hours. Combined use with α-adrenergic blockers (e.g., doxazosin, terazosin) may potentiate orthostatic hypotension due to overlapping vasodilatory effects. Titrate the α-blocker to a stable maintenance dose and ensure hemodynamic stability before introducing vardenafil at the lowest feasible dose.

Clinical pharmacology trials evaluating co-administration with tamsulosin 0.4 mg daily demonstrated no clinically significant blood-pressure reductions when vardenafil was given two hours after the α-blocker, underscoring the importance of temporal separation and dose adjustment. Additional interactions include moderate CYP3A4 inducers (e.g., rifampin, carbamazepine), which can lower systemic exposure, potentially requiring dosage escalation if clinically justified. Grapefruit juice inhibits enteric CYP3A4 and may unpredictably increase vardenafil bioavailability; patients should be advised to avoid large quantities or to maintain consistent intake patterns to minimize variability. Pharmacodynamic synergy with other vasodilators, antihypertensives, or alcohol could accentuate blood-pressure reductions, warranting patient counseling on positional dizziness and syncope risk. In randomized controlled trials, the most frequently reported adverse reactions included headache (up to 15 %), facial flushing (10 %), nasal congestion (7 %), dyspepsia (4 %), and dizziness (2 %).

Medical uses

Store vardenafil tablets at controlled room temperature, 20-25 °C (68-77 °F), with permissible excursions between 15 °C and 30 °C. Vardenafil for the treatment of erectile dysfunction: A critical review. Phosphodiesterase 5: Structure-function regulation and selectivity. PubChem compound summary for CID 135400189, vardenafil. Risk of death in patients with coronary artery disease taking phosphodiesterase 5 inhibitors.

Treatment & Diagnosis

Journal of the American College of Cardiology, 82(12), 1123-1135. Evaluation of vardenafil on cardiac repolarization in healthy men. The American Journal of Cardiology, 93(9), 1378-1383. Pharmacology and drug-interaction effects of phosphodiesterase 5 inhibitors. International Journal of Clinical Practice, 59(9), 1165-1170.

What are the serious side effects of vardenafil?

Ocular side effects of vardenafil: Results of a double-blind study. The Journal of Sexual Medicine, 17(11), 2057-2065. Cardiac safety in clinical trials of PDE5 inhibitors. Cardiology in Review, 13(4), 213-220. Simultaneous administration of vardenafil and tamsulosin in benign prostatic hyperplasia. These events were generally mild to moderate, transient, and self-limiting, correlating with peak plasma levels and attenuating upon repeated, intermittent use. Visual disturbances, predominantly a blue-green tinge or increased light sensitivity, occurred in ≤ 2% of subjects and resolved within hours of dosing cessation, consistent with transient PDE6 inhibition. Although rare, priapism-painful erections persisting beyond four hours-has been associated with PDE5 inhibitors, including vardenafil. Post-marketing pharmacovigilance identified fewer than 1 case per 50,000 prescriptions, yet the potential for irreversible tissue ischemia necessitates prompt medical intervention for prolonged erections. Counsel patients to seek emergency care if tumescence exceeds four hours. Additional serious but uncommon adverse events comprise sudden sensorineural hearing loss, non-arteritic anterior ischemic optic neuropathy, and myocardial infarction in predisposed individuals; establishing causality is challenging due to confounding vascular risk factors inherent to the target population. Cardiac electrophysiology investigations have shown small QTc prolongations that generally lack clinical consequence but underscore the need to avoid concomitant class IA or III anti-arrhythmic agents. Similarly, isolated reports of ventricular arrhythmias are confounded by underlying structural heart disease.

Post-authorization safety studies continue to monitor hepatic toxicity, hypersensitivity reactions, and potential drug-drug interactions, reinforcing the importance of ongoing pharmacovigilance in commercial preparations. Vardenafil is not indicated for use in women and carries no tadalista tablets established therapeutic role during pregnancy.

Vardenafil (Oral route)

In randomized controlled trials, the most frequently reported adverse reactions included headache (up to 15 %), facial flushing (10 %), nasal congestion (7 %), dyspepsia (4 %), and dizziness (2 %). These events were generally mild to moderate, transient, and self-limiting, correlating with peak plasma levels and attenuating upon repeated, intermittent use. Visual disturbances, predominantly a blue-green tinge or increased light sensitivity, occurred in ≤ 2% of subjects and resolved within hours of dosing cessation, consistent with transient PDE6 inhibition. Although rare, priapism-painful erections persisting beyond four hours-has been associated with PDE5 inhibitors, including vardenafil. Post-marketing pharmacovigilance identified fewer than 1 case per 50,000 prescriptions, yet the potential for irreversible tissue ischemia necessitates prompt medical intervention for prolonged erections.

What is vardenafil, and what is it used for?

Counsel patients to seek emergency care if tumescence exceeds four hours. Additional serious but uncommon adverse events comprise sudden sensorineural hearing loss, non-arteritic anterior ischemic optic neuropathy, and myocardial infarction in predisposed individuals; establishing causality is challenging due to confounding vascular risk factors inherent to the target population. Cardiac electrophysiology investigations have shown small QTc prolongations that generally lack clinical consequence but underscore the need to avoid concomitant class IA or III anti-arrhythmic agents. Similarly, isolated reports of ventricular arrhythmias are confounded by underlying structural heart disease. Post-authorization safety studies continue to monitor hepatic toxicity, hypersensitivity reactions, and potential drug-drug interactions, reinforcing the importance of ongoing pharmacovigilance in commercial preparations.

What should I do if I accidentally take too much vardenafil?

Vardenafil is not indicated for use in women and carries no tadalista tablets established therapeutic role during pregnancy. Animal reproduction studies conducted with doses generating exposures up to 18-fold higher than typical human AUC did not reveal teratogenicity, but delayed ossification and decreased neonatal survival were observed at maternally toxic doses, signifying class-related hemodynamic effects on uteroplacental perfusion. Because mechanistic data suggest theoretical impacts on vascular tone, the risk-benefit ratio for any off-label maternal use (e.g., pulmonary hypertension) remains uncertain. Current FDA guidance on reproduction-development toxicity testing stipulates that embryo-fetal development studies in at least two species (usually rats and rabbits) inform labeling when systemic maternal exposure approximates or exceeds anticipated clinical exposure. Safety extrapolation to humans relies on allometric scaling, placental transfer kinetics, and species-specific pharmacodynamics; therefore, absent positive human data, vardenafil should be avoided throughout pregnancy, and effective contraception is advised for women of reproductive potential participating in investigational protocols. Animal reproduction studies conducted with doses generating exposures up to 18-fold higher than typical human AUC did not reveal teratogenicity, but delayed ossification and decreased neonatal survival were observed at maternally toxic doses, signifying class-related hemodynamic effects on uteroplacental perfusion. Because mechanistic data suggest theoretical impacts on vascular tone, the risk-benefit ratio for any off-label maternal use (e.g., pulmonary hypertension) remains uncertain. Current FDA guidance on reproduction-development toxicity testing stipulates that embryo-fetal development studies in at least two species (usually rats and rabbits) inform labeling when systemic maternal exposure approximates or exceeds anticipated clinical exposure. Safety extrapolation to humans relies on allometric scaling, placental transfer kinetics, and species-specific pharmacodynamics; therefore, absent positive human data, vardenafil should be avoided throughout pregnancy, and effective contraception is advised for women of reproductive potential participating in investigational protocols.

Tainted supplements

American Journal of Cardiology, 92(8), 1048-1053. Clinical pharmacology review of vardenafil NDA 21-400. Simultaneous administration of vardenafil and tamsulosin does not cause hypotension. Grapefruit juice-drug interactions: A practical review. Store vardenafil tablets at controlled room temperature, 20-25 °C (68-77 °F), with permissible excursions between 15 °C and 30 °C. Vardenafil for the treatment of erectile dysfunction: A critical review. Phosphodiesterase 5: Structure-function regulation and selectivity. PubChem compound summary for CID 135400189, vardenafil.

Benefits of Levitra Jelly

Risk of death in patients with coronary artery disease taking phosphodiesterase 5 inhibitors. Journal of the American College of Cardiology, 82(12), 1123-1135. Evaluation of vardenafil on cardiac repolarization in healthy men. The American Journal of Cardiology, 93(9), 1378-1383.

• Vardenafil's active ingredient is vardenafil hydrochloride.
• It is often preferred for its rapid onset compared to others.
• It can be used successfully in men with nerve damage.
• Vardenafil may cause temporary visual color changes.
• It is not suitable for individuals with severe heart failure.
• Alcohol can impair the effectiveness of vardenafil.
• Taking it on an empty stomach may improve absorption.
• Avoid driving or operating machinery after taking Vardenafil.
• It is important to follow-up with your healthcare provider regularly.
• Do not double dose if the first dose is ineffective.
• Use the lowest effective dose to minimize side effects.

Pharmacology and drug-interaction effects of phosphodiesterase 5 inhibitors. International Journal of Clinical Practice, 59(9), 1165-1170. Ocular side effects of vardenafil: Results of a double-blind study. The Journal of Sexual Medicine, 17(11), 2057-2065. Cardiac safety in clinical trials of PDE5 inhibitors. Cardiology in Review, 13(4), 213-220. Simultaneous administration of vardenafil and tamsulosin in benign prostatic hyperplasia. Optimization of factors affecting vardenafil absorption using β-cyclodextrin. Pharmaceutical Development and Technology, 24(3), 354-364. Korean Journal of Urology, 47(9), 1001-1008. Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs, 4(5), 281-297. American Journal of Cardiology, 92(8), 1048-1053. Clinical pharmacology review of vardenafil NDA 21-400.

• Vardenafil contact info for adverse events reporting.
• It is one of several PDE5 inhibitors on the market.
• The medication requires sexual arousal to be effective.
• Take Vardenafil approximately 30 minutes before intimacy.
• Do not share your medication with others.
• Ensure proper hydration to help with absorption.
• The half-life of Vardenafil is around 4-5 hours.
• Do not use Vardenafil if you have had recent stroke or MI.
• Inform your doctor about all health conditions before use.
• Use Vardenafil responsibly to prevent dependency.
• Follow prescribed dosage for optimal results.

Simultaneous administration of vardenafil and tamsulosin does not cause hypotension. Grapefruit juice-drug interactions: A practical review.